All In Biotech

Drug Trial Radar · NCT03304496

Subcutaneous Nitroglycerin to Facilitate Trans-radial Access.

Subcutaneous Administration of Nitroglycerin to Facilitate Trans-radial Access in Coronary Procedures: a Randomized Clinical Trial (NITRAD-Sub Study).

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

SuspendedPivotal-lookingRandomized with 1,400 participants. This is a heuristic, not a regulatory label.

Status

Suspended

Enrollment

1,400

Planned (sponsor's estimate)

Start

Mar 30, 2018

Primary completion

Mar 30, 2019

Study completion Mar 31, 2026

Sponsor

Lead sponsor
Instituto Nacional de Cardiologia Ignacio ChavezAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 9, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, outcomes assessor)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Femoral artery approach to perform coronary procedures is considered the standard technique for vascular access due to optimal catheter control, lower thromboembolic complications and immediate access due to the large diameter of the artery. Trans-radial approach has been shown to reduce major bleeding complications, vascular complications related to the site of puncture, including death from all causes, and to prevent post-procedure limb rest, greater comfort for patients, immediate ambulation, early discharge and reduction of costs. Previous studies have shown that intravenous, topical and intraarterial use of nitroglycerin produces vasodilation of the radial artery. Extravascular (subcutaneous) administration of nitroglycerin is extremely effective in restoring the radial pulse, and allows adequate cannulation.

Conditions

  • Coronary Artery Disease

Interventions

  • Nitroglycerin 100 MCG/ML Injectable SolutionDrug

    Previously described.

  • Saline SolutionDrug

    Previously described.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Compound of crossover to femoral access and/or access site-related vascular complications.Time frame: Within 72 hours or at hospital discharge (whichever occurs first).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instituto Nacional de Cardiologia Ignacio Chavez

    Mexico City, Tlalpan, Mexico

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.